Evogene (EVGN) Director Percy John Receives 2,500 Stock Options

What Happened Percy Adrian John, a director of Evogene Ltd. (EVGN), was granted 2,500 stock options on September 4, 2026. The grant was reported on a Form 4 filed September 30, 2026. No cash was paid for the grant; the options carry an exercise price of NIS 1.75 per share (reported equivalent $0.58/share), so exercising all options would cost approximately $1,450. This is a compensatory award (grant), not an open-market purchase or sale.

Key Details

• Transaction date: September 4, 2026 (Form 4 filed September 30, 2026 — outside the typical 2-business-day reporting window).
• Grant: 2,500 stock options (transaction code A = award/grant).
• Exercise price: NIS 1.75 per share = $0.58 per share (Bank of Israel rate on grant date).
• Vesting: 25% per quarter beginning on the grant date; fully vested by September 4, 2027.
• Holdings after transaction: not specified in the row (footnote states the row is informational).
• Filing exhibit: Exhibit 24.1 — Power of Attorney.

Context This was a derivative grant (stock options) as part of compensation and does not represent an immediate purchase or sale of underlying shares. The options vest over one year in quarterly installments; there is no indication in the filing that any options were exercised or shares sold concurrently. The Form 4 was filed later than the usual 2-business-day window, which is noted for timeliness but does not change the substance of the grant.